DSP aims to extend Japan repaglinide use through new filing
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma (DSP) is looking to broaden the use of its antidiabetic Surepost (repaglinide; licensed from Novo Nordisk) in Japan through an approval filing for use in combination with either biguanide or thiazolidinedione drugs.